MX394625B - Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia - Google Patents
Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbiciaInfo
- Publication number
- MX394625B MX394625B MX2020012116A MX2020012116A MX394625B MX 394625 B MX394625 B MX 394625B MX 2020012116 A MX2020012116 A MX 2020012116A MX 2020012116 A MX2020012116 A MX 2020012116A MX 394625 B MX394625 B MX 394625B
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- low concentration
- control
- presbycia
- synergic
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000008029 eradication Effects 0.000 title 1
- 230000002195 synergetic effect Effects 0.000 title 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 abstract 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 abstract 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 abstract 2
- 229960001416 pilocarpine Drugs 0.000 abstract 2
- 201000010041 presbyopia Diseases 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 229960003679 brimonidine Drugs 0.000 abstract 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003655 bromfenac Drugs 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 208000001491 myopia Diseases 0.000 abstract 1
- 201000005111 ocular hyperemia Diseases 0.000 abstract 1
- 229960001528 oxymetazoline Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 239000005526 vasoconstrictor agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe una composición oftálmica para la prevención, el control y el tratamiento de los síntomas de la presbicia que comprende una combinación sinergística de pilocarpina, brimonidina, oximetazolina, ácido hialuronico, bromfenaco y opcionalmente un vasoconstrictor en una sola dosis de baja concentración para mejorar la capacidad de visión cercana e incrementar la profundidad de foco. Además, se reducen los efectos secundarios de la pilocarpina administrada por separado, como el enrojecimiento del ojo, dolor de cabeza y resequedad del mismo y tiene una mayor tolerancia en pacientes que padecen presbicia.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2020012116A MX394625B (es) | 2020-11-12 | 2020-11-12 | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia |
| PCT/MX2021/050074 WO2022103250A1 (es) | 2020-11-12 | 2021-11-11 | Composición oftalmológica sinérgica en dosis de baja concentración eficaz en la prevención, control y erradicación de la presbicia |
| CN202180081218.2A CN116981457A (zh) | 2020-11-12 | 2021-11-11 | 有效预防、控制和根除老花眼的低浓度剂量的协同眼科组合物 |
| KR1020237018378A KR20230098630A (ko) | 2020-11-12 | 2021-11-11 | 노안의 예방, 제어 및 근절에 효과적인 저농도 투여량의 상승적 안과 조성물 |
| US18/036,666 US20230414573A1 (en) | 2020-11-12 | 2021-11-11 | Synergistic ophthalmological composition in a low-concentration dose that is effective in the prevention, control and eradication of presbyopia |
| ARP210103132A AR124049A1 (es) | 2020-11-12 | 2021-11-12 | Composición oftalmológica sinérgica en dosis de baja concentración eficaz en la prevención, control y erradicación de la presbicia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2020012116A MX394625B (es) | 2020-11-12 | 2020-11-12 | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020012116A MX2020012116A (es) | 2022-08-09 |
| MX394625B true MX394625B (es) | 2025-03-24 |
Family
ID=81602593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012116A MX394625B (es) | 2020-11-12 | 2020-11-12 | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230414573A1 (es) |
| KR (1) | KR20230098630A (es) |
| CN (1) | CN116981457A (es) |
| AR (1) | AR124049A1 (es) |
| MX (1) | MX394625B (es) |
| WO (1) | WO2022103250A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024028816A1 (en) * | 2022-08-04 | 2024-02-08 | Bausch + Lomb Ireland Limited | Ophthalmic composition comprising pilocarpine and a redness reduction agent |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0724558D0 (en) * | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| US8299079B2 (en) * | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| AU2012311239B2 (en) * | 2011-09-20 | 2017-10-19 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
| US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| ES2538551B1 (es) * | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
| JP2017505805A (ja) * | 2014-02-11 | 2017-02-23 | オラシス ファーマシューティカルズ リミティド | 老眼矯正に使用される眼科用薬理組成物及びその投与 |
| CH711969A2 (it) * | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
| JP7297308B2 (ja) * | 2016-08-19 | 2023-06-26 | オラシス ファーマシューティカルズ リミティド | 眼科用医薬組成物及びそれに関する使用 |
-
2020
- 2020-11-12 MX MX2020012116A patent/MX394625B/es unknown
-
2021
- 2021-11-11 KR KR1020237018378A patent/KR20230098630A/ko active Pending
- 2021-11-11 WO PCT/MX2021/050074 patent/WO2022103250A1/es not_active Ceased
- 2021-11-11 US US18/036,666 patent/US20230414573A1/en active Pending
- 2021-11-11 CN CN202180081218.2A patent/CN116981457A/zh active Pending
- 2021-11-12 AR ARP210103132A patent/AR124049A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020012116A (es) | 2022-08-09 |
| KR20230098630A (ko) | 2023-07-04 |
| CN116981457A (zh) | 2023-10-31 |
| AR124049A1 (es) | 2023-02-08 |
| US20230414573A1 (en) | 2023-12-28 |
| WO2022103250A1 (es) | 2022-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7358221B2 (ja) | 老視を治療するための組成物及び方法 | |
| PH12021550882A1 (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| TW200633709A (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | |
| US20100286156A1 (en) | Collyrium For The Treatment Of Conical Cornea With Cross-Linking Trans-Epithelial Technique | |
| AU2016280615A1 (en) | Storage stable compositions and methods for the treatment of refractive errors of the eye | |
| WO2007108541A1 (ja) | キサンタンガムおよびブドウ糖を含有する眼科用組成物 | |
| MX346312B (es) | Tratamientos oftalmicos. | |
| WO2009137465A3 (en) | Compositions for treatment or prevention of pathological cardiac remodeling and heart failure | |
| US9833441B2 (en) | Compositions and methods for the treatment of presbyopia | |
| AU2011282683A1 (en) | Preservative free brimonidine and timolol solutions | |
| US20220105090A1 (en) | Compositions and methods for the treatment of eye conditions | |
| US20230404912A1 (en) | Compositions and methods for the treatment of presbyopia | |
| CN118922190A (zh) | 用于治疗眼病的组合物及方法 | |
| MX394625B (es) | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia | |
| MX2022001069A (es) | Composiciones y metodos para el tratamiento de la presbicia. | |
| WO2008048675A3 (en) | Treatment for age-related macular degeneration and other diseases of the eye | |
| Li et al. | Successful treatment of Lasiodiplodia theobromae keratitis–assessing the role of voriconazole | |
| MX2023002946A (es) | Composiciones y metodos para tratar presbicia, hipermetropia, astigmatismo, estereopsis disminuida, y sensibilidad al contraste disminuida. | |
| MY205498A (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| MX2021015292A (es) | Interacciones terapeuticas de leucometiltioninio. | |
| AU2020299145A8 (en) | Compositions and methods for treating eye diseases | |
| CA2453442A1 (en) | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases | |
| WO2023278979A3 (en) | Combination therapy treatment using transdermal delivery system | |
| MX2024016117A (es) | Triazoles para su uso en el tratamiento de enfermedades oculares | |
| EA201490173A1 (ru) | Фармацевтическая композиция для лечения преждевременной эякуляции и способ лечения преждевременной эякуляции |